Ending my Cardiology fellowship on a high note with presenting our analysis from the PARTNER trials today at #NYValves2025. We explored the long-term impact of patient-prosthesis mismatch on health status and QoL after TAVR or SAVR. Thankful to my mentors for this opportunity!

RT @SCAI: 🚑 Too many #STEMI patients still face treatment delays. Only 60% of direct arrivals and 50% of transfers meet #PCI time goals, re….

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

RT @TCTMD: Hospitals that struggle to meet time-to-treatment targets for STEMI patients have increases in in-hospital mortality and length….

RT @MyJSCAI: 📖In this single center study, #CTO #PCI was associated with improvement in #LVEF especially among patients with depressed base….

Excited to present a secondary analysis from the PARTNER trials at #NYValves2025. Honored to contribute to an outstanding lineup! @crfheart @tavrkapadia @djc795 @AdamGreenbaumMD @BabaliarosArgos @PPibarot @hahn_rt @PhilGenereuxMD @SuzanneJBaron @VinodThourani @EdwardsLifesci.

Finally, check out this accompanying editorial by @Drroxmehran: (5/5)

Failure to meet target FMC-to-device time, and presenting to low-performing hospitals were associated with increased risk of in-hospital mortality and longer hospital stays. However, hospital location and primary PCI volume were not associated with clinical outcomes (4/5)

High-performing hospitals with shorter target FMC-to-device times were also able to consistently meet other recommended metrics for #STEMI care compared with low- or intermediate-performing sites #GWTG (3/5)

In this #GWTG registry analysis of 73826 patients across 503 US sites, there was substantial variability in achieving target first medical contact (FMC)-to-device time across hospitals in both primary presentations to PCI-capable hospitals (≤90min) and transfers (≤120min) (2/5)

🚨🚨 Our new paper out today in @JAMACardio: We examined hospital-level variability in achieving guideline-recommended treatment times for #STEMI across the U.S.—and how hospital performance, geography and case volume relate to outcomes. (Short thread 1/5)

Incredibly grateful for a milestone week @HMethodistCV—graduated from Cardiology fellowship, delivered Grand Rounds on QoL in valve interventions, and received the Clinical Research Excellence Award. I am very proud to have trained here and thankful to all my amazing mentors! 🙏🏻

It was great presenting 2 late breaking studies from the Medtronic CoreValve/Evolut RCTs and the AHA GWTG-CAD registry @CRT_meeting. Thankful to my incredible mentors @HMethodistCV for their unwavering support! @SachinGoelMD @n_kleiman #MichaelReardon #LBCT

Excited to be giving 2 late breaking presentations in the upcoming @CRT_meeting this weekend!.

Our article about left ventricular function assessment after CTO PCI is now online in @MyJSCAI . This work is the first product from the @HMethodistCV CTO registry we put together . more to come soon! @AlpeshShahMD .

Very proud to match at my top choice for Interventional Cardiology— @EmoryUniversity. Excited to train under incredible operators @wissamj123 @drdevireddy @wjn_md @AdamGreenbaumMD @BabaliarosArgos @IsidaByku. Thankful to my family and mentors for their support! #Match2024

Strong Houston Methodist presence at the #TCT2024 conference from faculty, fellows, post docs, research coordinators and cath lab staff! Amazing science and people! @HMethodistCV @HMHCardioFellow @DeBakeyCVedu @WilliamZoghbi @crfheart

Thanks for highlighting our study from the TVT registry presented yesterday at #TCT2024! @djc795 @arnoldgehrke @jspertus @SachinGoelMD @n_kleiman .

Read our paper in @JACCJournals discussing the prognostic value of transmitral mean gradient in patients with primary and secondary MR undergoing mitral TEER #MitraClip.

RT @JACCJournals: In patients undergoing #TAVR or #MTEER, severe TR is associated with:.⬇️KCCQ score.⬆️Mortality.⬆️Readmission. 📎: https://….

Link to the paper:. With nice accompanying editorial by @AbdullahAlabcha @adnanalkhouli .